908 Devices Inc.
Business
908 Devices Inc. develops and commercializes purpose-built handheld and desktop analytical devices that bring molecular chemical and biochemical analysis to the point-of-need. Its main products leverage microscale mass spectrometry, optical spectroscopy (FTIR), microfluidics, and embedded analytics/machine learning to identify, separate and quantify trace and bulk chemical species, sold as devices such as MX908, ThreatID, ProtectIR, Rebel, Maverick, Maven, ZipChip Interface and related consumables and services. Key business segments include forensic and public safety applications, bioprocess monitoring and control, pharmaceutical/biopharma and life‑science research solutions. The company sells worldwide through direct field sales and a global network of channel partners, supporting government, industrial and academic customers.
Summary from filing dated 2025-03-07
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 56 | 48 | 50 | 47 | 42 | |
| Cost of revenue | 28 | 23 | 25 | 21 | 19 | |
| Gross profit | 28 | 25 | 25 | 26 | 23 | |
| Research and development | 16 | 15 | 22 | 18 | 13 | |
| Selling, general and administrative | 39 | 39 | 46 | 44 | 32 | |
| Change in fair value of contingent consideration | 14 | −13 | 107,000 | — | — | |
| Goodwill impairment | — | 41 | — | — | — | |
| Total operating expenses | 68 | 82 | 68 | 61 | 45 | |
| Loss from continuing operations | −39 | −57 | −43 | −35 | −22 | |
| Interest income | 4 | 4 | 6 | 2 | 548,000 | |
| Income from transition services agreement, net | 2 | — | — | — | — | |
| Other expense, net | −346,000 | −241,000 | −131,000 | −83,000 | −162,000 | |
| Total other income, net | 6 | 4 | 6 | 2 | −100,000 | |
| Loss from operations before income taxes | −33 | −53 | −37 | −34 | — | |
| Income tax expense | 66,000 | 300,000 | 200,000 | 0 | — | |
| Net loss from continuing operations | −33 | −53 | — | — | — | |
| Net income (loss) from discontinued operations, net of tax | 53 | −19 | — | — | — | |
| Net income (loss) attributable to common stockholders | 19 | −72 | −36 | −34 | −22 | |
| Net loss from continuing operations per share attributable to common stockholders, basic | −0.93 | −1.56 | — | — | — | |
| Net loss from continuing operations per share attributable to common stockholders, diluted | −0.93 | −1.56 | — | — | — | |
| Net income (loss) from discontinued operations per share attributable to common stockholders, basic | 1.47 | −0.56 | — | — | — | |
| Net income (loss) from discontinued operations per share attributable to common stockholders, diluted | 1.47 | −0.56 | — | — | — | |
| Net income (loss) per share attributable to common stockholders, basic | 0.54 | −2.12 | −1.13 | −1.07 | −0.79 | |
| Net income (loss) per share attributable to common stockholders, diluted | 0.54 | −2.12 | −1.13 | −1.07 | −0.79 | |
| Weighted average common shares outstanding, basic | 36 | 34 | 32 | 31 | 28 | |
| Weighted average common shares outstanding, diluted | 36 | 34 | 32 | 31 | 28 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2024 2024-06-30 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 71 | 44 | — | 121 | 188 | |
| Cash and cash equivalents from continuing operations | — | 43 | — | — | — | |
| Marketable securities | 42 | 26 | — | 25 | — | |
| Accounts receivable, net of allowance for credit losses of $147 and $524 at December 31, 2025 and December 31, 2024 | 11 | 9 | — | 9 | 10 | |
| Inventory | 13 | 11 | — | 15 | 13 | |
| Prepaid expenses and other current assets | 7 | 4 | — | 4 | 5 | |
| Current assets of discontinued operations | — | 10 | — | — | — | |
| Total current assets | 145 | 103 | — | 174 | 216 | |
| Operating lease, right-of-use assets | 4 | 4 | 600,000 | 6 | 4 | |
| Property and equipment, net | 4 | 2 | — | 3 | 3 | |
| Intangible assets, net | 36 | 39 | — | 8 | 8 | |
| Other long-term assets | 471,000 | 511,000 | — | 1 | 1 | |
| Non-current assets of discontinued operations | — | 12 | — | — | — | |
| Total assets | 190 | 159 | — | 203 | 243 | |
| Accounts payable | 2 | 1 | — | 1 | 1 | |
| Accrued expenses | 7 | 7 | — | 9 | 9 | |
| Deferred revenue | 9 | 10 | — | 11 | 8 | |
| Operating lease liabilities | 681,000 | 1 | — | 2 | 1 | |
| Contingent consideration | 16 | — | — | — | — | |
| Current liabilities of discontinued operations | — | 5 | — | — | — | |
| Total current liabilities | 34 | 25 | — | 23 | 19 | |
| Operating lease liabilities, net of current portion | 4 | 3 | — | 4 | 3 | |
| Deferred revenue, net of current portion | 8 | 10 | — | 9 | 11 | |
| Contingent consideration, net of current portion | — | 2 | — | — | — | |
| Other long-term liabilities | 30,000 | 2 | — | — | 555,000 | |
| Non-current liabilities of discontinued operations | — | 5 | — | — | — | |
| Total liabilities | 46 | 45 | — | 37 | 52 | |
| Commitments and contingencies (Note 17) | — | — | — | — | — | |
| Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued or outstanding at December 31, 2025 and December 31, 2024, respectively | — | — | — | — | — | |
| Common stock, $0.001 par value; 100,000,000 shares authorized; 36,321,866 shares and 35,098,493 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 36,000 | 35,000 | — | 33,000 | 32,000 | |
| Additional paid-in capital | 367 | 356 | — | 335 | 324 | |
| Accumulated other comprehensive income | 54,000 | 1 | — | 1 | 798,000 | |
| Accumulated deficit | −223 | −243 | — | −171 | −134 | |
| Total stockholders' equity | 144 | 115 | — | 165 | 191 | |
| Total liabilities and stockholders' equity | 190 | 159 | — | 203 | 243 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net income (loss) | 19 | −72 | −36 | −34 | −22 | |
| Depreciation and amortization expense | 4 | 5 | 2 | 2 | 925,000 | |
| Stock-based compensation expense | 10 | 12 | 10 | 7 | 3 | |
| Provision for inventory obsolescence | 513,000 | 653,000 | 663,000 | 376,000 | 191,000 | |
| Net amortization of premiums and accretion of discounts on marketable securities | −637,000 | 13,000 | −301,000 | — | — | |
| Loss on disposal of property and equipment | 133,000 | 54,000 | — | — | — | |
| Gain on sale of Desktop Portfolio, net of transaction costs | −56 | — | — | — | — | |
| Provision for credit losses | — | 176,000 | 386,000 | — | — | |
| Change in fair value of contingent consideration | 14 | −13 | 107,000 | 161,000 | — | |
| Deferred income tax | — | −283,000 | −305,000 | −129,000 | — | |
| Accounts receivable, net | 220,000 | −3 | 680,000 | 6 | −11 | |
| Inventory | −4 | −2 | −4 | −5 | −4 | |
| Prepaid expenses and other current assets | −3 | −445,000 | −513,000 | 844,000 | −4 | |
| Other long-term assets | 211,000 | 559,000 | −135,000 | −93,000 | −476,000 | |
| Accounts payable and accrued expenses | −6 | 2 | 2 | 452,000 | 3 | |
| Deferred revenue | −3 | −368,000 | 179,000 | 2 | 5 | |
| Right-of-use operating lease assets | 2 | 2 | 2 | 1 | 1 | |
| Operating lease liabilities | −2 | −2 | −2 | −1 | −1 | |
| Net cash used in operating activities | −24 | −30 | −25 | −21 | −29 | |
| Purchases of property and equipment | −955,000 | −602,000 | −2 | −2 | −737,000 | |
| Purchases of marketable securities | −64 | −56 | −49 | — | — | |
| Acquisition of businesses, net of cash acquired | −2 | −45 | — | — | — | |
| Proceeds from sale of Desktop Portfolio | 70 | — | — | — | — | |
| Proceeds from maturities of marketable securities | 48 | 55 | 25 | — | — | |
| Net cash provided by (used in) investing activities | 51 | −46 | −26 | −16 | −737,000 | |
| Payments for withholding taxes on vested awards | −833,000 | −1 | −776,000 | −262,000 | — | |
| Proceeds from issuance of common stock | 864,000 | 1 | 936,000 | 2 | 852,000 | |
| Payments for contingent consideration | −728,000 | −417,000 | −1 | — | — | |
| Net cash used in financing activities | −697,000 | −376,000 | −16 | 1 | 95 | |
| Effect of foreign exchange rate changes on cash and cash equivalents | 27,000 | −65,000 | 13,000 | 18,000 | — | |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 26 | −77 | −67 | −36 | 65 | |
| Transfers of inventory to property and equipment | 983,000 | 1 | 1 | 887,000 | 940,000 | |
| Fair value of common stock issued for acquisition of RedWave Technology | — | 9 | — | — | — | |
| Cash (received) paid for income tax | −66,000 | 184,000 | — | — | — |